not used title
not used title
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and our industry is not immune. We need to stand up to racism and injustice because failing to do so impacts our collective wellbeing. Our industry is committed to learning and leading us forward.
I had the opportunity to connect with Percival Barretto-Ko, President of Astellas US, about the company’s efforts in this space.
Stephen Ubl (SU): Thanks for taking the time to chat, Percival. This year, the world has banded together to fight COVID-19, and our industry is working tirelessly to that end. Can you speak to the work Astellas is doing for patients and communities in response to the pandemic?
Percival Barretto-Ko (PBK): COVID-19 has underscored our commitment to place the patient at the center of everything we do. With the patient serving as our North Star, the Astellas community banded together quickly at the onset of the pandemic to seek ways to serve the patients and the communities where we live and where we work.
With this in mind, one of Astellas’ first steps was to ensure there would be no disruption in our supply chain so that patients could be reassured they would not lose access to critical medicines. In addition, we halted clinical trial enrollments to avoid putting patients and healthcare professionals at risk. We also strengthened our patient support programs so people who have lost their jobs or were concerned about a loss of income could still get the medications they need. Months later, when it was deemed safe to continue with our trials, we adjusted our operations to accommodate patients who were not able to visit a doctor’s office by implementing initiatives like direct-to-patient drug shipments. This enabled us to ensure clinical trial continuity while minimizing delay in advancing the development of new medicines.
At Astellas, we are keenly aware of the communities around us. This year, we donated millions of dollars to global and national relief efforts and to programs here in Illinois, where our U.S. headquarters are based. In addition, we have sought opportunities to provide financial assistance and resources to hard-hit areas and their healthcare workers. I am proud of the way my Astellas colleagues have stepped up to meet unique needs within their communities – and to support their efforts, we increased the number of paid volunteer days available to employees. We also expanded our benefits to include job search assistance for our employees’ immediate family members who may have lost their jobs.
Culture and leadership are tested in times of uncertainty. It is incredibly gratifying to see how the biopharmaceutical industry broadly and Astellas specifically have risen to the challenge set by the worldwide pandemic – responding with groundbreaking innovation and a commitment to protecting the patients who rely on us.
SU: While defeating COVID-19 has been our industry’s main priority this year, our nation has been grappling with some major issues around racial inequality. I understand that Astellas has been proactive in creating a more inclusive work environment. Can you tell me about that?
PBK: I’m glad you asked, Steve. While building a diverse workforce and cultivating an inclusive culture has always been a top priority for Astellas, recent events have heightened our awareness that more must be done to advance the cause of equality in our country, and we all have a responsibility to move our society forward. We want to live up to our commitments as a company, an industry and a nation.
Engagement, diversity and inclusion have to be more than buzz words. They have to be deeply embedded into an organization’s DNA, aligned with a sense of ownership and accountability. At Astellas, our work to weave D&I throughout the fabric of our organization didn’t happen overnight. We began the foundational efforts nearly a decade ago and have made continual progress since, with several key milestones in 2014 and over the past three years.
Our journey took a leap forward in 2014, when we created seven employee impact groups (EIGs) for African-American, Asian, Hispanic, LGBTQ, military, disabled, and women employees. These groups, which introduce, coordinate, and support employees with shared interests, backgrounds and goals, have not only enhanced our cultural awareness, but have played critical roles in advising the business and producing an impact internally and externally.
In 2018, we further strengthened our commitment to diversity and inclusion by recruiting a new head of D&I to enhance our efforts and cement a sustainable strategy going forward. Last year, we formed a Diversity & Inclusion Governance Council, which I co-chair with our chief medical officer, Dr. Bernie Zeiher. The council includes more than two dozen leaders from across our organization to help ensure D&I remains a strategic imperative at Astellas. Through the council, we have established meaningful measures to keep us on track to meet related goals and to continue improving over time.
These steps helped us strengthen our commitment to engagement, diversity and inclusion and prepared us to swiftly respond to the events of 2020. Early into the pandemic, our Asian EIG held an internal event focused on discrimination that Asian Americans experienced during the onset of the COVID-19 pandemic. Following the death of George Floyd, our leadership issued a public statement standing in solidarity with all people working for equity and racial justice, and we implemented several employee support opportunities. Our African American EIG hosted an internal all-employee virtual forum that provided an opportunity to hear about the experiences and perspectives from some of our Black and Brown colleagues, and to discuss ways we can do more as an organization and as individuals through allyship and advocacy. We plan to continue these “Diversity Dialogues,” as they remind us how important it is to never stop learning, and never stop listening to others’ stories.
Finally, in October, I was proud to sign the CEO Action for Diversity & Inclusion pledge as a way of formalizing Astellas’ efforts to advance our diverse workforce and inclusive workplace goals.
SU: We know that from a scientific perspective, diversity is vital to conducting clinical trials. What work has Astellas done recently to make sure clinical trial participants are representative of patient populations?
PBK: This is a personal issue for me. Born and raised in the Philippines by a Korean mother and a Filipino-Chinese father, I am fully aware that my ethnic background is not necessarily reflected in the clinical trials taking place today. We know that some drugs can affect various racial and ethnic populations differently and so there is an obligation for all of us in the biopharmaceutical ecosystem to strengthen the diversity in our clinical trials. According to the National Institutes of Health, fewer than 10 percent of all enrolled trial participants are from minority populations.
I applaud PhRMA for its leadership in developing the recent industry-wide principles on enhancing clinical trial participation. The principles offer a constructive guide to help build on our existing efforts to work collaboratively to diversify our clinical trial enrollment.
At Astellas, among recent efforts, our teams have been working diligently to make the clinical trial process more understandable and accessible for potential participants. We’ve streamlined our contact processes for clinical trial recruitment and utilized health literacy best practices to make our forms and tools more reader-friendly. In addition, we’re increasing clinical trial participation and are focusing our selection of clinical trial sites around geographic regions with high populations of racially diverse patients. We also are working with patient advocacy groups and looking at decentralizing trials to make access easier.
The pandemic has underscored the health inequities that exist in our country – and we recognize that enhanced diversity in our trials can be an important part of the solution.
SU: That is interesting, thank you for sharing. I know your team has been doing work internally to attract and retain talent with diverse perspectives and backgrounds. What lessons have you learned that others can take with them in their hiring process?
PBK: It struck me when I read a recent Gallup report showing half of all workers in the U.S. are unhappy in their jobs. If an organization has a high proportion of its workforce not enjoying what it’s doing and not wanting to be there, then performance will inevitably suffer.
At Astellas, we have grounded ourselves on “3 Ps” – patients, people, performance. At the core of this philosophy is a simple message - when you have a tenacious, singular focus on the patient – and the right people in place – performance follows.
Last year, we launched an ambitious “three-year people strategy” aimed at attracting, retaining and developing top talent. In our hiring, we are conscious of building a workforce of high-potential, high-performing colleagues of all backgrounds. These efforts run in parallel with our D&I strategy. We are also working with our managers at all levels to help generate an inclusive atmosphere and culturally competent leadership to get the most from the talent we have. To this end, we recently rolled out a training program focused on implicit biases in the hiring process and leading diverse teams.
We believe that a commitment to diversity and inclusion in all that we do is essential to our mission of delivering value to patients. By embracing and prioritizing diversity amongst our people, we can engender greater creativity and depth into our planning and execution across the board. We are proud of the strides made thus far in our journey, and we look forward to new learnings and growth opportunities going forward.
As always, you can stay up-to-date with the work the biopharmaceutical industry is doing to combat COVID-19 here.
Stephen J. Ubl
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America.
Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics."
Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.
Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).
He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.
https://x.com/steveubl
https://www.linkedin.com/in/steveubl/
President and Chief Executive Officer
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
New research: Industry sponsored clinical trials contribute billions to state economies
March 6, 2025
Recent events highlight progress on health equity
October 22, 2024
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
October 21, 2024
Hispanic Heritage Month: Fighting for Hispanic patients
October 7, 2024
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
September 20, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
Women’s Health Month: A conversation with Sage
May 23, 2024
Championing cancer equity: Our drive for healthier AANHPI communities
May 1, 2024
New analysis: Accelerated approval pathway is changing lives in underserved communities
April 30, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
December 7, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
October 27, 2023
What you should know about protecting your health this fall
October 16, 2023
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
September 25, 2023
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
September 12, 2023
Decentralized clinical trials and the future of drug development
August 9, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
Between hope and despair: Improving cancer outcomes
July 11, 2023
A conversation with Dr. Mike Ybarra on the current state of COVID-19
June 27, 2023
ICYMI: PhRMA CMO Dr. Michael Ybarra speaks with Dr. Fabian Sandoval about clinical trial diversity
May 16, 2023
PhRMA awards grant to Emerson Diversity Health Foundation
April 19, 2023
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
April 19, 2023
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
April 13, 2023
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
March 30, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
U.S. must address IP and market access barriers abroad to protect American innovation
January 31, 2023
Using traditional HTAs to determine coverage threatens patient access to medicine
December 14, 2022
Traditional HTAs keep diverse patients out of the conversation
December 7, 2022
Word of the Month: What is TRIPS?
November 29, 2022
TRIPS waiver expansion risks public health
November 14, 2022
Expanding the WTO intellectual property waiver will hurt American jobs
November 9, 2022
Traditional HTA methods treat everyone like the “average” patient
November 7, 2022
Word of the Month: Long COVID
October 19, 2022
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
October 13, 2022
Partnerships are driving global COVID-19 treatment access
September 22, 2022
The dangers of expanding the TRIPS waiver
September 19, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
July 15, 2022
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
July 14, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
July 6, 2022
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
June 16, 2022
Potential gene therapies bring hope to patients with sickle cell disease
June 6, 2022
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
May 23, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
A conversation with Barry Greene, CEO of Sage Therapeutics
May 4, 2022
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
April 28, 2022
Stephanie Dyson of BMS on reducing health disparities
April 27, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
February 24, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
February 16, 2022
Protecting U.S. innovation abroad to support economic and pandemic recovery
February 1, 2022
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
January 24, 2022
Navigating the patient experience in the time of COVID-19
December 6, 2021
Global COVID-19 vaccination matters now and for the future
November 29, 2021
Announcing CAREs Grant Round 4
November 12, 2021
Announcing CAREs Grant Round 4
November 12, 2021
Understanding breakthrough COVID-19 infections
November 11, 2021
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
October 29, 2021
The important role of antivirals in the fight against COVID-19
October 6, 2021
Understanding Long COVID-19
September 29, 2021
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
September 27, 2021
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
September 8, 2021
The impact of monoclonal antibodies and COVID-19 recovery
September 2, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Driving further innovation is critical to global vaccine equity
August 24, 2021
Supporting country readiness to boost global vaccine access
August 12, 2021
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
August 5, 2021
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
August 4, 2021
Increasing global access to vaccines by optimizing production
July 29, 2021
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
July 23, 2021
Guest Post: A patient’s story of the long-term health impacts of COVID-19
July 21, 2021
Dose sharing as a part of the COVID-19 global vaccine equity strategy
July 20, 2021
Promoting global vaccine equity while protecting innovation
July 15, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
PhRMA awards $75,000 to fund initiatives to reduce health inequities
July 1, 2021
Watch: Building trust and enhancing clinical trial diversity
June 24, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
Americans 12 years of age and older are eligible for COVID-19 vaccines
June 17, 2021
PhRMA hosts first stakeholder workshop on clinical trial diversity
June 11, 2021
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
June 9, 2021
A year later: Reflections on the meaning of equity
May 25, 2021
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
May 21, 2021
Supporting India during the devastating coronavirus surge
May 20, 2021
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
May 14, 2021
The Biden Administration allows politics to upend a pragmatic pandemic response
May 14, 2021
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
May 6, 2021
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
May 5, 2021
Reflecting on Mental Health Awareness Month
May 4, 2021
American leadership on innovation policy is essential to global health progress
May 4, 2021
Patient safety is at the heart of COVID-19 vaccine R&D
April 26, 2021
PhRMA member companies share how they are improving clinical trial diversity
April 14, 2021
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
April 12, 2021
Diversifying clinical trials and fighting disease requires equity and trust
April 12, 2021
Building confidence in the COVID-19 vaccine through education
March 22, 2021
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
March 8, 2021
Intellectual property is the key to vaccine development, manufacturing and technology sharing
March 5, 2021
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
February 24, 2021
Fighting variants of COVID-19
February 22, 2021
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
February 22, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
February 12, 2021
Lessons learned from COVID-19: The way we develop new medicines is changing
February 10, 2021
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
January 28, 2021
Growing trend: Increased vaccine confidence
January 28, 2021
Election insights: Common ground areas to address Americans’ health care concerns
January 26, 2021
Paper finds gaps in health data are a barrier to health equity
January 11, 2021
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
January 8, 2021
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
December 21, 2020
Election insights: Voter priorities in the states
December 17, 2020
Increasing diversity at investigator sites could increase minority participation in clinical trials
December 17, 2020
Report highlights biopharmaceutical industry’s commitment to D&I
December 17, 2020
Insights from the election: Meeting voters where they are on health care
December 15, 2020
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
December 9, 2020
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
December 7, 2020
Guest Post: Bringing our best to the fight against COVID-19
December 3, 2020
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
November 24, 2020
Committing to diversity, equity and inclusion: A call to action for clinical trials
November 19, 2020
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
November 18, 2020
Just released: PhRMA members’ new clinical trial diversity principles
November 18, 2020
Deep dive: The issues that drove the 2020 vote
November 13, 2020
Understanding the emergency use authorization process for COVID-19 vaccines
November 12, 2020
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
November 2, 2020
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
November 2, 2020
Voters want to address the real drivers of health care costs for patients and the system
November 2, 2020
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
October 13, 2020
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
October 12, 2020
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
October 1, 2020
Leading researchers to spotlight the critical role of biopharmaceutical R&D
October 1, 2020
Sharing rebates can improve access to medicines and increase health equity
September 30, 2020
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
September 30, 2020
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
September 23, 2020
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
September 17, 2020
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
September 16, 2020
PhRMA will continue to advocate for equity within our industry
September 10, 2020
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
September 2, 2020
Three ways the pharmaceutical industry can positively impact health equity
September 1, 2020
The 2020 We Work for Health Champion Awards showcase the best of our industry
August 27, 2020
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
August 24, 2020
Summer reading in the age of COVID-19
August 21, 2020
Systemic racism is as real as any disease, and our industry is not immune
August 20, 2020
The patient perspective navigating COVID-19
August 11, 2020
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
August 4, 2020
Executive order threatens R&D when we need it most to fight COVID-19
July 30, 2020
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
July 22, 2020
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
July 21, 2020
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
July 13, 2020
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
July 13, 2020
New initiative to bridge the gap on antimicrobial innovation
July 9, 2020
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
June 30, 2020
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
June 29, 2020
In combating COVID-19, science is how we get back to normal
June 24, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
Guest post: A post-pandemic crisis: The mental toll on America
June 16, 2020
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
June 11, 2020
PhRMA awards $100,000 to fund projects that address health inequalities
June 10, 2020
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
June 5, 2020
What scientific experts are saying about vaccine safety
June 4, 2020
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
May 29, 2020
IP Explained: Intellectual property system working to combat COVID-19
May 28, 2020
Guest Post: What will we learn from COVID-19?
May 27, 2020
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
May 18, 2020
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
May 4, 2020
Guest Post: Preserving clinical research sites during the coronavirus pandemic
April 29, 2020
Observing National Minority Health Month in the age of COVID-19
April 24, 2020
New report shows nearly 260 vaccines in development, including dozens for COVID-19
April 23, 2020
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
April 15, 2020
Guest post: Securing the health care supply chain during COVID-19
April 14, 2020
To the millions affected by COVID-19
April 9, 2020
New infographic: How we are fighting COVID-19
April 8, 2020
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
April 6, 2020
The biopharmaceutical industry’s unique role in responding to COVID-19
April 2, 2020
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
April 1, 2020
COVID-19 Response: Supporting the frontline
March 30, 2020
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
March 26, 2020
America’s biopharmaceutical companies are working around the clock to beat coronavirus
March 20, 2020
Guest post: Takeda’s efforts to address COVID-19
March 19, 2020
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
March 16, 2020
ICYMI: Continued biopharmaceutical action on COVID-19
March 6, 2020
Helping those affected by the coronavirus
February 20, 2020
Clinical Trials Awareness Week: Celebrating innovation in clinical research
May 15, 2019
Clinical trials impact state economies
May 3, 2019
Examining the truth behind clinical trial costs
October 2, 2018
New report details the setbacks and challenges to Alzheimer’s research
September 12, 2018
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
May 25, 2018
Bringing innovation to clinical trial design
April 23, 2018
EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing
November 29, 2017
Guest Post: Film chronicles clinical trials ‘paying it forward’
November 28, 2017